INTRODUCTION
Tumor necrosis factor-alpha (TNF-α) is a pleiotropic cytokine involved in inflammation, immunity and also cellular organization. It was first isolated from the serum of Bacillus-Calmette-Guerin-infected mice treated with endotoxin, inducing hemorrhagic tumor necrosis. TNF-α is a type II transmembrane protein with an intracellular N-terminus. It is a soluble 17 kDa molecule (157 amino acids) that binds as a homotrimer to 2 distinct homotrimeric receptors on the cell surface: TNFRI (p55 receptor) and TNFRII (p75 receptor). TNF-α is synthesized as a 26 kDa membrane-bound propeptide (233 amino acids) and is secreted upon cleavage by TNF-α-converting enzyme (TACE). The 26 kDa form is also functional, binding to TNFRII via direct cell-to-cell contact. It is produced by macrophages, neutrophils, fibroblasts, NK cells, astrocytes, T and B cells, Kupffer cells, smooth muscle Papadopoulou et al 
MATERIALS AND METHODS

Study population
Fifty-six consecutive patients with primary breast carcinoma admitted to the University General Hospital of Alexandroupolis were included in the present populationbased, prospective, case-control study. Patients' age and menopausal status were recorded and body mass index (BMI), expressed as weight/height 2 (kg/m 2 ), was used as the standard for the assessment of obesity. Overweight was defined as a BMI ≥25.0. Patients were also divided into 2 different self-reported religious groups: Greek Christians (43 patients) and Greek Muslims (13 patients) . Forty-five healthy women with no evidence of neoplastic disease who visited our hospital for routine health checkups were recruited as controls. They were frequency matched to the breast cancer patients based upon age (±5 years) and religion/ethnicity. The diagnosis of breast cancer was confirmed by histological examination, using specimens obtained from biopsy or surgical resection. Tumors were graded according to the criteria described by Bloom and Richardson (25) and tumor stage was assigned according to the TNM classification defined by the International Union Against Cancer (26) . The immunohistochemical method for the evaluation of estrogen receptor (ER), progesterone receptor (PR) and HER-2 proteins was described in some detail in a recent report (27) . ER and PR values were calculated as a percentage of cancer cells showing nuclear reactivity within a given cell population; all optical fields were counted in each case at 200x and expressed as the mean of all counts. Tumors with ER or PR values >10% were considered positive. HER-2 was evaluated following a similar approach to ER and PR, and tumors expressing cell membrane reactivity in >10% of neoplastic cells were considered positive. Written informed consent was obtained from all women and the regional ethics committee approved the study.
Genotyping the HER-2 codon 655
Approximately 10 mL of peripheral blood was collected from each study participant with a standard venipuncture technique in tubes containing ethylenediaminetetraacetic acid (EDTA). Genomic DNA was isolated from whole blood by means of a Puregene DNA purification kit (Gentra Systems Inc., Minneapolis, MN, USA). The genotype of the HER-2 gene was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP)-based assay. The primers, based on the protocol used by Xie et al (17) , were as follows: forward: 5'-AGA GCG CCA GCC CTC TGA CGT CCA T-3'; reverse: 5'-TCC GTT TCC TGC AGC AGT CTC CGC A-3'. DNA was amplified in a MJ Research PTC-100 Thermal Cycler. The PCR reaction was carried out in 50 μL of reaction mixture (7) reported that chronic TNF-α production sustains many processes that provide the mutated cell with its survival advantage, such as autocrine growth signals, insensitivity to anti-growth signals, angiogenesis, evasion of apoptosis, invasion and metastasis, as well as unlimited replicative potential. So, inhibition of TNF-α as a key proinflammatory molecule may lead to novel cancer treatments (8) .
The epidermal growth factor receptor-2 (HER-2; also known as c-erbB-2), is a 185 kDa transmembrane glycoprotein receptor with tyrosine kinase activity and a member of the EGFR family (9) . It plays an important role in the regulation of cell growth, differentiation and survival and is involved in the regulation of normal breast growth and development. However, HER-2 overexpression has been found in a variety of malignant diseases, including invasive breast carcinomas, where amplification, protein overexpression -or both -of this receptor have been found in 20-35% of tumors (10, 11) . HER-2 is an established prognostic factor in breast cancer, and is the target of trastuzumab therapy (12, 13) . Overexpression of HER-2 correlates with poor survival of breast and ovarian cancer patients and induces resistance to TNF-α, which causes cancer cells to escape from the host immune defence (14) .
The gene encoding the HER-2 receptor is a natural target for the investigation of polymorphisms that might indicate resistance or susceptibility to the development of breast cancer. One common variant, a single nucleotide polymorphism (SNP) at codon 655 (Ile655Val) of the HER-2 gene (located in the transmembrane region of the corresponding HER-2 protein), has been reported in various cancer types (15) . The change from isoleucine (ATC triplet) to valine (GTC triplet) is suggestive of increased dimerization and tyrosine kinase activity, which can result in cell transformation (16) . Xie et al (17) first reported the association of this SNP with an increased risk of breast cancer (odds ratio 1.4). However, subsequent studies have cast doubt on this association, which remains controversial (18) (19) (20) (21) . The divergent results may be partly explained by differences in the polymorphism of the HER-2 codon 655 between ethnic groups (22) . In 2 previous studies, we have shown an allelic imbalance of Ile655Val SNP between Greek Christian and Greek Muslim populations of Thrace and its possible implication in a more aggressive phenotype of breast cancer associated with a poor prognosis (23, 24) .
The aim of the present study was to investigate the diagnostic significance of serum levels of TNF-α for breast cancer and to examine their association with the clinicopathological parameters of breast cancer patients and the HER-2 Ile655Val polymorphism. The prognostic relevance of TNF-α alone and in combination with the HER-2 Ile655Val polymorphism was also evaluated. explore the independent effect of TNF-α levels and their combination with HER-2 SNP on overall survival. Patient age, tumor size, lymphovascular invasion, histological type, clinical stage, histological grade, lymph node status, ER, PR and HER-2 status, and HER-2 SNP were included as potential confounders in the multivariate model. All tests were 2-tailed and statistical significance was assigned to p values <0.05.
RESULTS
Characteristics of the study population
The study population consisted of 56 breast cancer patients with a median age of 64 years (range, 33-80 years; mean age ± SD, 61.34 ± 11.64 years) and 45 healthy controls with a median age of 59 years (range, 31-82 years; mean age ± SD, 57.20 ± 12.04 years). The demographic characteristics of patients and controls are summarized in Table I . There were no significant differences in age (p=0.176), religion/ethnicity (p=0.517), menopausal status (p=0.453), and BMI (p=0.250) between patients and controls.
Histological type, lymphovascular invasion, tumor size, histological grade, clinical stage, lymph node status, and immunohistochemical expression of ER, PR and HER-2 protein were recorded for each breast cancer patient (Tab. I). Regarding tumor histology, 43 (76.8%) tumors were ductal and 13 (23.2%) lobular carcinomas. More than 80% were invasive carcinomas and 60.7% were sized between 2 and 5 cm (T2). Nine (16.1%) carcinomas were well differentiated (G1), 11 (19.6%) were moderately differentiated (G2), and 36 (64.3%) were poorly differentiated. Twenty-seven cases (48.2%) were stage II, while in 30 patients (53.6%) lymph node metastases were detected. ER, PR and HER-2 protein positivity was detected in 66.1%, 44.6% and 55.4% of the patients, respectively.
TNF-α and breast cancer risk
The serum levels of TNF-α were significantly higher in patients with primary breast cancer than in the control group (19.18 pg/mL, IQR, 12.04-32.51 pg/mL vs 7.92 pg/mL, IQR, 4.41-12.14 pg/mL, p<0.001; Fig. 1 ). For the evaluation of the diagnostic significance of TNF-α in breast cancer, the AUC was 0.848 (95% CI, 0.774-0.923, p<0.001). A cutoff point of 11.00 pg/mL was established to classify breast cancer patients. This optimal cutoff yielded a high sensitivity (86%), a specificity of 71%, a positive predictive value of 79%, and a negative predictive value of 80%. The overall accuracy of women's classification according to this cutoff point was 79.2% (80 of 101 cases), while Cohen's kappa indicated substantial agreement (k=0.575, p<0.001).
containing 500 ng of genomic DNA, 300 nM of each primer, 350 μM of each dNTP, and PCR buffer composed of 1.75 mM MgCl 2 and 2.5 U Taq Polymerase (Roche). The reaction mixtures were heated to 94 o C for 30 seconds followed by 35 cycles at 94 o C for 30 seconds, 62 o C for 30 seconds, and 72 o C for 30 seconds. A final extension step was included at 72 o C for 7 minutes. The PCR products (148 bp) were digested with 5 U BsmAI (Invitrogen, USA) at 37 o C overnight, and separated by agarose gel electrophoresis (agarose concentration 3%).
Measurement of serum TNF-α
Peripheral blood samples were collected from each patient before surgery. After centrifugation at 3000 rpm for 20 minutes, serum samples were frozen and stored at -70 o C until biochemical assessment. Quantitative sandwich enzyme immunoassay (ELISA) was performed for measuring concentrations of serum TNF-α by means of a commercially available kit (ImmunoKontact, AMS Biotechnology, UK).
Statistical analysis
Statistical analysis of the data was performed using the Statistical Package for the Social Sciences (SPSS), version 13.0 (SPSS, Inc., Chicago, IL, USA). The normality of quantitative variables was tested with the Kolmogorov-Smirnov test. Serum TNF-α levels were expressed as the median and interquartile range (IQR) (Kolmogorov-Smirnov test: p=0.022 and p=0.020 for the control and patient groups, respectively). Categorical variables were expressed as frequencies (and percentages). The chisquare test was used to evaluate any potential association between categorical variables. The median test was used to assess differences of TNF-α levels between 2 or more groups of patients. A multivariate stepwise linear regression was constructed to explore the independent effect of patient and disease characteristics on serum TNF-α levels. The logarithmic transformation of TNF-α levels was used (Kolmogorov-Smirnov test: p=0.020 and p=0.200 for the initial and transformed TNF-α levels, respectively). For the evaluation of the diagnostic significance of TNF-α levels, the area under the receiver operating characteristic (ROC) curve (AUC) was calculated. Sensitivity, specificity, positive and negative predictive values were also calculated, while Cohen's kappa was used to assess agreement. The value with the shortest distance from the curve to the point with both maximum sensitivity and specificity, i.e., the point (0.0, 1.0), was selected as the cutoff to classify breast cancer patients. Survival rates were calculated with the Kaplan-Meier method and the statistical difference between survival curves was determined with the log-rank test. Multivariate Cox proportional hazards regression analysis, using a backward selection approach, was performed to immunohistochemical expression of HER-2, increased levels of TNF-α were found among patients with positive lymph nodes and in HER-2 overexpressing tumors, but these associations were not statistically significant (p=0.166 and p=0.142, respectively). No significant association was found between serum levels of TNF-α and patients' age (p=0.789), menopausal status (p=0.849), BMI (p=0.321), ethnicity (p=0.162), tumor histology (p=0.992) and immunohistochemical expression of ER (p=0.324) and PR (p=0.323).
To evaluate the association between serum levels of TNF-α and HER-2 SNP, we analyzed the Ile655Val genotypes in all breast cancer patients. Ile-Ile, Ile-Val and Val-Val genotypes were found in 15 (26.8%), 22 (39.3%) and 19 (33.9%) patients, respectively. The frequency of the Val allele among the breast cancer patients was 53.6%. We have recently shown that the Val allele confers a modest increase in breast cancer risk and is associated with a more aggressive phenotype of the tumor (23) . A statistically significant association was found between serum levels of TNF-α and HER-2 SNP (p<0.001). Ile-Val and Val-Val genotypes had highly significant TNF-α elevation compared to homozygous Ile-Ile (p=0.016 and p<0.001, respectively). No significant difference in TNF-α levels was found between Ile-Val and Val-Val patients (p=0.126) (Fig. 2) .
Multivariate stepwise linear regression analysis revealed that poor differentiation (p=0.007), the presence of more than 3 positive lymph nodes (p=0.050), and Valcontaining genotypes (p=0.003) remained significant independent determinants of high levels of TNF-α in breast cancer patients, explaining 46.6% of their variance (R 2 =0.466; adjusted R 2 =0.345).
TNF-α and tumor characteristics
The associations of serum levels of TNF-α with clinicopathological parameters are presented in Table II . Statistically significantly elevated levels of TNF-α were found in larger tumors (p=0.038), poorly differentiated tumors (p=0.011), and in patients with more than 3 positive lymph nodes (p=0.046). A marginal trend towards higher values of TNF-α was found in invasive tumors (p=0.069) and in advanced-stage carcinomas (p=0.062). With regard to lymph node status and the 
TNF-α and survival
In order to assess the TNF-α-dependent overall survival, a serum TNF-α level of 21.55 pg/mL (the 95th percentile of the control group) was selected as the cutoff point to subdivide breast cancer patients into 2 groups. Follow-up data were available for all patients. The median HER-2 SNP was entered in the regression analysis, the simultaneous presence of the Val-Val genotype with high levels of TNF-α remained an independent determinant for poor survival (hazard ratio 10.3, 95% CI 1.1-92.6, p=0.046 compared to most favorable subgroup; hazard ratio 3.2, 95% CI 0.8-17.7, p=0.092 compared with patients having high levels of TNF-α alone). difference between survival rates over time (p=0.024 and p=0.030, respectively), with patients with high levels of TNF-α having a worse prognosis (Fig. 3) . The mortality rate was significantly higher in patients with high levels of TNF-α compared to patients with low levels of TNF-α (40.0% vs 16.1%, p=0.045); patients with high levels of TNF-α were almost 4 times more likely to die of cancer than those with low levels of TNF-α (hazard ratio 3.3, 95% CI 1.1-9.8, p=0.032).
Regarding the prognostic significance of HER-2 SNP on overall survival, in a previous paper (24) we showed that the Val-Val genotype was independently associated with a poor prognosis (hazard ratio 9.2, 95% CI 1.1-80.1, p=0.045). A combined analysis of TNF-α levels and HER-2 SNP revealed that the subgroup of patients characterized by the simultaneous presence of the Val-Val genotype and high levels of TNF-α had a significantly reduced survival not only compared with the most favorable group (low TNF-α levels and Ile-Ile or Ile-Val genotypes; p<0.001), but also compared with patients having high levels of TNF-α alone (p=0.048) (Fig. 4) . In particular, the mean survival time was 46 ± 2 months (95% CI 43-49 months) in patients with low levels of TNF-α and Ile-Ile or Ile-Val genotypes, 39 ± 3 months (95% CI 33-46 months) in patients with high levels of TNF-α alone, 39 ± 4 months (95% CI 32-46 months) in homozygous Val-Val patients, and 25 ± 2 months (95% CI 20-30 months) in Val-Val patients with high levels of TNF-α.
Further investigation with multivariate Cox proportional hazards regression analysis revealed that serum TNF-α remained an independent prognostic factor of worse overall survival (hazard ratio 5.0, 95% CI 1.3-19.9, p=0.021). When the combination of TNF-α and stimulation through the PI3K/Akt pathway. Their results provide a molecular explanation for the finding that HER-2/neu-overexpressing breast cancer cells are more resistant to TNF-induced apoptosis, leading to poor prognosis and shortened survival. In our series HER-2 overexpression was rather higher (55.4%), as indeed in other series (27, 49) , with respect to the 20-35% rate reported in the literature (10, 11) .
HER-2 is associated with poor prognosis in breast and ovarian cancer patients, as it enhances the metastatic potential of cancer cells and induces resistance to Taxol and TNF (50) . Further understanding of the HER-2/neumediated antiapoptotic pathway may pave the way for novel anticancer therapies for HER-2/neu-overexpressing breast and ovarian cancers. In a recent paper (23) we revealed an allelic imbalance of the Ile655Val polymorphism of HER-2 between Greek Christian and Greek Muslim populations of Thrace and we showed that the Val allele could be associated with the development of breast cancer and may serve as an indicator of genetic susceptibility to this disease. Moreover, we demonstrated an association of HER-2 genotype with more advanced clinicopathological characteristics and immunohistochemical HER-2 overexpression as well as high serum HER-2 levels, which may indicate its possible implication in a more aggressive phenotype. In the current study the increased levels of TNF-α found in HER-2-overexpressing tumors did not reach statistical significance, in contrast with the findings of Saglam et al (51) , who showed that plasma TNF-α levels were positively correlated with overexpression of HER-2 in patients with primary breast carcinoma. However, we found that serum TNF-α levels increase significantly in the presence of a Val allele. This finding may support the suggestion that a functional interaction between TNF-α and this SNP of the HER-2 gene may contribute to the progression of breast cancer. Multivariate analysis showed that lymph node involvement remained a strong independent prognostic factor for higher TNF-α levels. These results confirm our suggestion that the HER-2 receptor, with its more aggressive phenotype (Val-Val), by creating more constant dimers could enhance its activity as a tyrosine kinase and interact with other signal transduction molecules involved in antiapoptotic pathways (50, 52, 53) , even in cases with no overexpression of HER-2.
Many studies have reported a relation between survival and TNF-α expression (54) . Higher TNF-α concentrations were predictive of poor survival independent of disease stage in patients with chronic lymphocytic leukemia. By contrast, in patients with metastatic breast cancer, serum TNF-α levels, along with fasting serum insulin, were independent predictors of overall and progression-free survival. In our study, although the duration of follow-up was short (median, 30 months), the preliminary results showed that high serum TNF-α levels were significantly
DISCUSSION
We demonstrated in this study that serum TNF-α levels were significantly higher in breast cancer patients than in healthy women. This finding is consistent with previous studies which associated the detection of abnormally high levels of TNF-α protein not only in breast cancer (28, 29) but also other human cancers such as ovarian (30) , renal cell (31) , prostate (32), pancreas (33) , oral cavity (34) , and several types of cancer (35) , as well as some hematological malignancies (36, 37) . Both TNF-α mRNA and TNF-α protein have been found in human epithelial ovarian tumor cells and in infiltrating macrophages (38) . The current study has demonstrated a very high diagnostic significance of serum TNF-α levels for breast cancer (AUC, 0.848). The optimal cutoff value of 11.0 pg/mL for predicting breast cancer yielded a sensitivity of 86%, a specificity of 71%, and an accuracy of 79%.
Our results indicate that serum levels of TNF-α are significantly associated with larger tumors, poorly differentiated tumors, and the presence of more than 3 positive lymph nodes; lymphovascular invasion and advanced clinical stage were determinants of high TNF-α levels of marginal significance. Multivariate analysis showed that poor differentiation and extensive lymph node involvement (>3 positive nodes) remained strong independent prognostic factors for higher TNF-α levels. Our findings demonstrate that TNF-α contributes not only to the development but also the progression and spread of breast cancer. TNF-α, a potent proinflammatory cytokine, can be used by tumors to induce other downstream molecules involved in the metastatic process, as has been shown by a number of studies on intraperitoneal invasion (39) , lung metastases (40) , and increased metastatic tumor activity (41) . In histological samples of breast cancer, increased TNF-α staining correlated with angiogenesis (42) . TNF-α seems to play an important role in cancer invasion due to its association with adhesion molecules such as E-cadherin, via a Src kinase-dependent mechanism (43), ICAM-1 in the context of the extracellular matrix in a thyroid cancer cell line (44) , as well as integrins, which induce invasion, in vitro, in specific tumor cells (45) . In another experiment on pancreatic cancer cells, TNF-α stimulated E-selectin expression, thus increasing the cells' adhesion capacity and leading to the tumor's entry into the vasculature (46) . TNF-α has also been found to increase the motility of cancer cells, which seems to be cell dependent (47) .
Varela et al (48) have shown that TNF-α may induce carcinogenesis by upregulating NF-kB, leading to the upregulation of other proteins that cause cell proliferation and morphogenesis. Overexpression of the HER-2/neu oncogene may play a critical role in this process, as also reported by Zhou et al (14) , who found that overexpression of HER-2/neu activates Akt and NF-kB without extracellular Financial support: No specific grants or funds were received. The present study was supported by the general annual public funds of the Medical School, Democritus University of Thrace.
Experiments on human subjects: The procedures followed in this study were in accord with the ethical standards of the committee on human experimentation. associated with reduced overall survival. In multivariate Cox regression analysis, TNF-α remained an independent predictor of poor prognosis, even after including other well-established prognostic factors. The combined analysis of TNF-α levels and Ile655Val HER-2 polymorphism gave additional prognostic information regarding survival compared to serum TNF-α alone. The simultaneous presence of high TNF-α levels with the Val-Val genotype defined a high-risk subgroup of patients, independently associated with a worse survival compared to patients having high serum TNF-α levels alone.
Our findings suggest that serum TNF-α is involved in malignancy and lymph node metastasis and could be used clinically as a useful tumor marker for diagnosis, tumor spread, and disease outcome. They also provide clinical evidence for a significant association between HER-2 Ile655Val SNP and serum TNF-α, resulting in a more aggressive tumor phenotype and poor prognosis. Longer follow-up is required to confirm the results on the survival association.
